Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.03
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
89
90
Next >
Beyond The Numbers: 8 Analysts Discuss Merck & Co Stock
February 02, 2024
Via
Benzinga
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Merck Stock Rocketed Nearly 5% Skyward Today
February 01, 2024
The company reported healthy sales growth and proffered encouraging guidance to boot.
Via
The Motley Fool
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
Merck (MRK) Q4 2023 Earnings Call Transcript
February 01, 2024
MRK earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Merck & Company Inc. (NYSE: MRK) Records 52-Week High Thursday Morning
February 01, 2024
Via
Investor Brand Network
Merck & Co's Earnings: A Preview
January 31, 2024
Via
Benzinga
How Is The Market Feeling About Merck & Co?
January 30, 2024
Via
Benzinga
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
February 01, 2024
Wall Street rebounds after Fed meeting with all major indices up, buoyed by earnings & dovish expectations. Probability for March cut at 41%, speculators increase bets for future cuts. Jobless claims...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth
February 01, 2024
Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, and EPS outlook for 2024.
Via
Benzinga
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
February 01, 2024
After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February.
Via
Benzinga
Why the quality investor may take a look at MERCK & CO. INC. (NYSE:MRK).
January 30, 2024
Why MERCK & CO. INC. (NYSE:MRK) Deserves Consideration as a Quality Investment.
Via
Chartmill
Merck Reports A Surprise Profit As Keytruda Sales Continue On Their Warpath
February 01, 2024
Analysts expected an 11-cent per-share loss from Merck in the fourth quarter. But the company came out ahead.
Via
Investor's Business Daily
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
February 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Powell Dubious On March Cut, Markets Slide
January 31, 2024
Markets pulled back from their steady trading levels today once Fed Chair Jerome Powell, speaking at his press conference following the latest Fed meeting
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
IBM, Verizon, Merck stocks lead Dow to new highs
January 31, 2024
The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For February 1, 2024
February 01, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...
Via
Benzinga
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings
January 29, 2024
Merck stock has gained 20% since Nov. 28; a technical signal suggests the rally isn't over. Keytruda approvals also drive optimism.
Via
Benzinga
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
January 29, 2024
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.
Via
Benzinga
Hope for Kidney Cancer Patients, Merck's Keytruda Cuts Risk Of Death By 38% Following Surgery
January 29, 2024
Results from Merck's Phase 3 KEYNOTE-564 trial. Keytruda, an adjuvant treatment for renal cell carcinoma, shows a 38% improvement in overall survival at 57.2 months.
Via
Benzinga
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
January 28, 2024
These companies can perform well through this bull run and beyond.
Via
The Motley Fool
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
January 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck's Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
January 26, 2024
Merck's Keytruda results in treating high-risk urothelial carcinoma. Discover statistically significant improvements in disease-free survival at ASCO GU Cancers Symposium 2024.
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
January 26, 2024
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
Via
Benzinga
Topics
Government
Exposures
Political
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
January 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
January 25, 2024
LAVA Therapeutics collaborates with Merck on a clinical trial for anti-PD-1 therapy Keytruda in metastatic castration-resistant prostate cancer.
Via
Benzinga
3 S&P 500 Stocks With 127% to 170% Upside in 2024, According to Select Wall Street Analysts
January 25, 2024
Wall Street's benchmark index is comprised of 500 companies, three of which could deliver triple-digit upside in the new year.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today?
January 24, 2024
Evaxion Biotech revolutionizes cancer vaccine development, targeting AI-identified ERVs. Preclinical activities underway; Proof-of-Concept data expected by 2H 2024.
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
89
90
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.